Evidence map›Paper›PMID 26579439›Full record

ReviewActa pharmaceutica Sinica. B2015

Bile acid nuclear receptor FXR and digestive system diseases.

Lili Ding, Li Yang, Zhengtao Wang, Wendong Huang

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
246citing papers in PubMed, 4 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

246 citing papers in PubMed, 4 syntheses or guidelines pooled it, 454 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Regulation of Tph cell differentiation via farnesoid X receptor of dendritic cells in inflammatory bowel disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

186 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Lili DingShanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China ; Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA.
Li YangShanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Zhengtao WangShanghai Key Laboratory of Complex Prescriptions and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Wendong HuangDepartment of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA.
Shanghai University of Traditional Chinese Medicine · CNCity Of Hope National Medical Center · US

Funding

MiRNAs in hepatocellular carcinoma development and treatmentR01CA139158 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI HUANG, WENDONG, YU, HUA E · 2011 to 2021
$3.7M
NCI NIH HHS R01 CA139158
6 · The paper itself

Abstract

Bile acids (BAs) are not only digestive surfactants but also important cell signaling molecules, which stimulate several signaling pathways to regulate some important biological processes. The bile-acid-activated nuclear receptor, farnesoid X receptor (FXR), plays a pivotal role in regulating bile acid, lipid and glucose homeostasis as well as in regulating the inflammatory responses, barrier function and prevention of bacterial translocation in the intestinal tract. As expected, FXR is involved in the pathophysiology of a wide range of diseases of gastrointestinal tract, including inflammatory bowel disease, colorectal cancer and type 2 diabetes. In this review, we discuss current knowledge of the roles of FXR in physiology of the digestive system and the related diseases. Better understanding of the roles of FXR in digestive system will accelerate the development of FXR ligands/modulators for the treatment of digestive system diseases.

Indexed as

6-ECDCA, 6α-ethyl-chenodeoxycholic acidAF2, activation domainANGTPL3, angiopoietin-like protein 3AOM, azoxymethaneAP-1, activator protein-1Apo, apolipoproteinASBT, apical sodium-dependent bile salt transporterBAAT, bile acid-CoA amino acid N-acetyltransferaseBACS, bile acid-CoA synthetaseBAs, bile acidsBile acidsBMI, body mass indexBSEP, bile salt export pumpCA, cholic acidCDCA, chenodeoxycholic acidCD, Crohn׳s diseaseColorectal cancerCREB, cAMP regulatory element-binding proteinCYP7A1, cholesterol 7α-hydroxylasedb/db, diabetic miceDBD, DNA binding domainDCA, deoxycholic acidDSS, dextrane sodium sulfateERK, extracellular signal-regulated kinaseFABP6, fatty acid-binding protein subclass 6Farnesoid X receptorFFAs, free fatty acidsFGF19, fibroblast growth factor 19FGFR4, fibroblast growth factor receptor 4FXRE, farnesoid X receptor response elementFXR, farnesoid X receptorG6Pase, glucose-6-phosphataseGastrointestinal tractGLP-1, glucagon-like peptide 1GLUT2, glucose transporter type 2GPBAR, G protein-coupled BA receptorGPCRs, G protein-coupled receptorsGSK3, glycogen synthase kinase 3HDL-C, high density lipoprotein cholesterolHNF4α, hepatic nuclear factor 4αI-BABP, intestinal bile acid-binding proteinIBD, inflammatory bowel diseaseIL-1, interleukin 1Inflammatory bowel diseaseKLF11, Krüppel-like factor 11KRAS, Kirsten rat sarcoma viral oncogene homologLBD, ligand binding domainLCA, lithocholic acidLPL, lipoprotein lipaseLRH-1, liver receptor homolog-1MCA, muricholicacidMRP2, multidrug resistance-associated protein 2NF-κB, nuclear factor-kappa BNOD, non-obese diabeticNRs, nuclear receptorsOSTα, organic solute transporter alphaOSTβ, organic solute transporter betaPEPCK, phosphoenol pyruvate carboxykinasePGC-1α, peroxisome proliferators-activated receptor γ coactivator protein-1αSHP, small heterodimer partnerSREBP-1c, sterol regulatory element-binding protein 1cSTAT3, signal transducers and activators of transcription 3T2D, type 2 diabetesTLCA, taurolithocholic acidTNBS, trinitrobenzensulfonic acidTNFα, tumor necrosis factors αType 2 diabetesUC, ulcerative colitisUDCA, ursodeoxycholic acidVSG, vertical sleeve gastrectomy

Identifiers

PMID26579439
PMCPMC4629217
OpenAlexW2012065014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.